Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 13Glioblastoma 10Glioma 7Astrocytoma 6Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 4Neoplasms 4Brain Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Stomach Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Oligodendroglioma 2Melanoma 2Carcinoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Diseases 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Seroma 1Rectal Neoplasms 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Patient Preference 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Inflammatory Breast Neoplasms 1

Interventions

pertuzumab 1pazopanib 1decitabine and cedazuridine drug combination 1daratumumab 1Trastuzumab 1Surgical Procedures, Operative 1Sunitinib 1Sorafenib 1Radiotherapy 1Opdualag 1Nivolumab 1Injections, Subcutaneous 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Patient Preference × Surgical Procedures, Operative × Clear all
NCT05415215 2026-02-10

ProHer

Hoffmann-La Roche

Phase 3 Completed
346 enrolled 20 charts
Breast

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡